secretagogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-23 and is reviewed periodically as new material appears.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
=== Near-surface divergence === In the United States, as a high-pressure system moves eastward out to the Atlantic, northerly winds are reduced along the southeast coast. If northeasterly winds persist in the southern damming region, net divergence is implied. Near-surface divergence reduces the depth of the cold dome as well as aid the sinking of air, which can reduce cloud cover. The reduction of cloud cover permits solar heating to effectively warm the cold dome from the surface up.
Kopeček, "Refolding Hydrogels Self-Assembled from N-(2-Hydroxypropyl)methacrylamide Graft Copolymers by Antiparallel Coiled-Coil Formation". Biomacromolecules 7, 1187–1195 (2006) J.-G. Shiah, Y. Sun, C.M. Peterson, R.C. Straight, J. Kopeček, "Antitumor Activity of N-(2-Hydroxypropyl)methacrylamide Copolymer-Meso Chlorin e6 and Adriamycin Conjugates in Combination Treatments". Clinical Cancer Research 6, 1008–1015 (2000) T. Minko, P. Kopečková, J. Kopeček, "Efficacy of Chemotherapeutic Action of HPMA Copolymer-Bound Doxorubicin in a Solid Tumor Model of Ovarian Carcinoma". International Journal of Cancer 86, 108–117 (2000) Z.-R. Lu, P. Kopečková, J. Kopeček, "Polymerizable Fab’ Antibody Fragments for Targeting of Anticancer Drugs". Nature Biotechnology 17, 1101–1104 (1999) C. Wang, R.J. Stewart, J. Kopeček, "Hybrid Hydrogels Assembled from Synthetic Polymers and Coiled-Coil Protein Domains". Nature 397, 417–420 (1999) N.L. Krinick, Y. Sun, D. Joyner, J.D. Spikes, R.C. Straight, J. Kopeček, "A Polymeric Drug Delivery System for the Simultaneous Delivery of Drugs Activatable by Enzymes and/or Light". Journal of Biomaterials Science, Polymer Edition 5, 303–324 (1994) R. Duncan, P. Kopečková, J. Strohalm, I.C. Hume, J.B. Lloyd, J. Kopeček, "Anticancer Agents Coupled to N-(2-Hydroxypropyl)methacrylamide Copolymers. 2. Evaluation of Daunomycin Conjugates In Vivo against L1210 Leukaemia". British Journal of Cancer 57, 147–156 (1988) P. Rejmanová, J. Pohl, M. Baudyš, V. Kostka, J. Kopeček, "Polymers Containing Enzymatically Degradable Bonds. 8.
The medical equipment approach involves combining a continuous glucose monitor and an implanted insulin pump that can function together with a computer-controlled algorithm to replace the normal function of the pancreas. The development of continuous glucose monitors has led to the progress in artificial pancreas technology using this integrated system. Unlike the continuous sensor alone, the closed-loop system requires no user input in response to reading from the monitor; the monitor and insulin pump system automatically delivers the correct amount of hormone calculated from the readings transmitted. The system is what makes up the artificial pancreas device.
Sources: en.wikipedia.org
== Applications and uses == Biologically, deficiencies in endoglycosidases can lead to several diseases, including lysosomal storage diseases and multisystem diseases, most of which involve the nervous system. N-linked glycans can provide structural components of cell walls and extracellular matrices, modify protein stability and solubility, direct trafficking of other glycoproteins, and mediate cell signaling (cell-cell interactions and cell-matrix interactions). N-linked glycosylation can be seen in antibodies, on cell surfaces, and on various proteins throughout the matrix. Alterations in glycosylation are often acquired in cases of cancer and inflammation, which may have important functional consequences. To that end, PNGase F and other endoglycosidases can be used to study oligosaccharides and characterize glycoproteins. PNGase F lacks selectivity for outer carbohydrate structure, resulting in broad specificity, making it a useful tool for investigating glycoprotein structure and function. In most instances, proteins of interest are denatured and treated with PNGase F. Following this, they are either subjected to gel electrophoresis, in which protein migration changes due to the deglycosylation by PNGase F, or are analyzed via mass spectrometry, by which the oligosaccharide can be characterized and the protein or peptide fragment from which it came can be characterized.
== Further reading == Mortison, JD; Sherman, DH (2010). "Frontiers and opportunities in chemoenzymatic synthesis". J Org Chem. 75 (21): 7041–51. doi:10.1021/jo101124n. PMC 2966535. PMID 20882949. Kim, Jinhyun; Lee, Sahng Ha; Tieves, Florian; Paul, Caroline E.; Hollmann, Frank; Park, Chan Beum (5 July 2019). "Nicotinamide adenine dinucleotide as a photocatalyst". Science Advances. 5 (7): eaax0501. doi:10.1126/sciadv.aax0501.
==== Member of the Royal Victorian Order (MVO) ==== Christian Mary Bailey, Curator to The Prince of Wales. Frederick Booth, Chief Heraldic Painter, College of Arms. Ann Teresa Brown, , lately British Overseas Trade Board. Matthew Nicholas Butler, lately Assistant Private Secretary to The Prince of Wales Pamela Margaret Clark, Deputy Registrar, Royal Archives, Windsor Castle. Claire Elizabeth Hunter-Craig, Secretary, Household of The Duke of Edinburgh. Reginald Elliott, Higher Executive Officer, Crown Estate, Windsor. Valerie Winifred Hampton, Personal Secretary to Princess Alexandra, the Honourable Lady Ogilvy. Chief Yeoman Warder Norman William Jackson, HM Tower of London. Alexander Masson, Head Gamekeeper, Balmoral Estate. John Ronald Pepper, lately of Collingwood & Company Limited. Inspector Stephen Lionel Robinson, Royalty and Diplomatic Protection Department, Metropolitan Police. Eileen Margaret Sly, lately the Westminster Abbey Trust. William Albert Stewart, Head Warden, Palace of Holyroodhouse. Prudence Sarah Sutcliffe, Assistant Curator of the Print Room, Windsor Castle. Lieutenant Colonel Patrick John Tabor, lately Equerry to The Prince of Wales.
== Medical uses == Spironolactone is used in the treatment of heart failure with reduced ejection fraction (HFrEF), where evidence shows that it reduces the risk of heart failure hospitalisation and mortality when added to standard therapy. Multiple studies show that spironolactone improves left ventricular diastolic function in patients with heart failure with preserved ejection fraction HFpEF, though without benefits in death from any cause or overall hospitalisation. One randomised controlled trial showed a modest reduction in hospitalisation due to heart failure. A secondary analysis of TOPCAT suggested possible benefit in patients with both HFpEF and resistant hypertension, but this has not been confirmed in a prospective trial designed for this subgroup. Spironolactone is an effective fourth-line add-on therapy for lowering blood pressure in resistant hypertension that remains uncontrolled despite an ACE inhibitor or ARB, calcium channel blocker, and diuretic. It is also used to treat edematous conditions such as nephrotic syndrome or ascites in people with liver disease, essential hypertension, low blood levels of potassium, secondary hyperaldosteronism (such as occurs with liver cirrhosis), and Conn's syndrome (primary hyperaldosteronism). The most common use of spironolactone is in the treatment of heart failure. On its own, spironolactone is only a weak diuretic because it primarily targets the distal nephron (collecting tubule), where only small amounts of sodium are reabsorbed, but it can be combined with other diuretics to increase efficacy.
Sources: en.wikipedia.org
=== Antidote to heparin === Protamine sulfate has been given to counteract the anticoagulant effect of heparin (1 mg per 100 units of heparin that had been given over the past 6 hours). It may be used in those who overdose on heparin or to reverse heparin's effect when it is no longer needed.
or 140 different polypeptides in the library. This peptide library would be useful for analyzing the effect of the post-translational modification acetylation on lysine which neutralizes the positive charge. Having the library of different peptides at residue 2 and 3 would let the investigator see if some change in chemical properties in the N-terminal tail of the ligated protein makes the protein more useful or useful in a different way.
The Medicinal Liquor Prescriptions Act of 1933 was a law passed by Congress in response to the abuse of medicinal liquor prescriptions during Prohibition. Gilbert Paul Jordan (aka The Boozing Barber) was a Canadian serial killer who is believed to have committed the so-called "alcohol murders" between 1965–c. 2004 in Vancouver, British Columbia.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.